Catalyst Pharmaceuticals, Inc.
General ticker "CPRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.7B (TTM average)
Catalyst Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -1.7%.
Estimated limits based on current volatility of 1.3%: low 22.59$, high 23.17$
Factors to consider:
- Total employees count: 181 (+8.4%) as of 2024
- Top business risk factors: Product commercialization failure, Regulatory and compliance, Clinical trial delays, Cybersecurity threats, Geopolitical risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [17.31$, 29.05$]
- 2025-12-31 to 2026-12-31 estimated range: [19.16$, 31.93$]
Financial Metrics affecting the CPRX estimates:
- Positive: with PPE of 9.7 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 39.68 > 18.64
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Positive: Shareholder equity ratio, % of 85.46 > 63.39
- Positive: Inventory ratio change, % of 0.04 <= 0.84
- Positive: 6.82 < Operating cash flow per share per price, % of 9.46
- Positive: Investing cash flow per share per price, % of -0.02 > -0.66
Short-term CPRX quotes
Long-term CPRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $214.20MM | $398.20MM | $491.73MM |
| Operating Expenses | $112.36MM | $311.39MM | $296.61MM |
| Operating Income | $101.84MM | $86.81MM | $195.12MM |
| Non-Operating Income | $2.88MM | $7.70MM | $21.14MM |
| R&D Expense | $19.79MM | $93.15MM | $12.65MM |
| Income(Loss) | $104.72MM | $94.51MM | $216.26MM |
| Taxes | $21.64MM | $23.10MM | $52.37MM |
| Profit(Loss)* | $83.08MM | $71.41MM | $163.89MM |
| Stockholders Equity | $300.42MM | $387.88MM | $727.63MM |
| Inventory | $6.80MM | $15.64MM | $19.54MM |
| Assets | $375.63MM | $470.11MM | $851.41MM |
| Operating Cash Flow | $116.05MM | $143.60MM | $239.81MM |
| Capital expenditure | $0.03MM | $81.74MM | $0.56MM |
| Investing Cash Flow | $9.21MM | $-293.50MM | $-0.56MM |
| Financing Cash Flow | $1.69MM | $-10.86MM | $140.66MM |
| Earnings Per Share** | $0.80 | $0.67 | $1.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.